John Travaline, MD
Pulmonary Disease · Philadelphia, PANPI 1417945460
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,022 of the $1,465 with a category attached, or 69.8%. Intuitive Surgical accounts for 74.7% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2022 at $1,022 and has fallen 94.2% since, to $59 in 2025.
Across 23 payments — averaging $63.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$1K
- Harmony Biosciences LLC$273
- Jazz Pharmaceuticals Inc.$28
- Actelion Pharmaceuticals US, Inc.$19
- Cardinal Health 200 LLC$18
- Resmed Corp$17
- plus $16 from 1 others
What the payments were for
- Travel & lodging$1,02270%
- Food & beverage$44330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 9 | $1,095 |
| Harmony Biosciences LLC | 9 | $273 |
| Jazz Pharmaceuticals Inc. | 1 | $28 |
| Actelion Pharmaceuticals US, Inc. | 1 | $19 |
| Cardinal Health 200 LLC | 1 | $18 |
| Resmed Corp | 1 | $17 |
| Insmed, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,465 in reported general payments places this provider in the 55th percentile of 703 pulmonary disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 67 | $54,853 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 49 | $22,746 |
| Breo ElliptaFluticasone/Vilanterol | 40 | $20,989 |
| Spiriva RespimatTiotropium Bromide | 18 | $14,248 |
| EliquisApixaban | 17 | $14,135 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $13,719 |
| Incruse ElliptaUmeclidinium Bromide | 26 | $11,740 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 15 | $10,289 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 61 | $9,756 |
| SymbicortBudesonide/Formoterol Fumarate | 32 | $8,548 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 111 | $3,042 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 17 | $2,383 |
| Wixela InhubFluticasone Propion/Salmeterol | 15 | $1,435 |
| Ipratropium Bromide | 12 | $932 |
| Fluticasone Propionate | 65 | $859 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Philadelphia
- Gerard CrinerPhiladelphia$657K
- Parth RaliPhiladelphia$314K
- Steven GellerPhiladelphia$274K
- Christopher ManleyPhiladelphia$262K
- Jeffrey EdelsonPhiladelphia$233K
- Benjamin WindPhiladelphia$168K
- Boyd HehnPhiladelphia$157K
- Gary AaronsonPhiladelphia$122K
- Friedrich KueppersPhiladelphia$100K
- Philip SilkoffPhiladelphia$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.